Changchun High-tech Subsidiary Receives FDA Orphan Drug Designation for GenSci128, Targeting Gastric CancerCoinLive·Mar 24 at 04:36 AM000661+1.97%
GenSci128 Receives Orphan Drug Designation for Pancreatic Cancer TreatmentCoinLive·Mar 10 at 05:12 AM000661+1.97%
CCHT's "New Drug for Treating Male Children's Developmental Disorders" Sparks Stock Price Surge; Company Responds: Project is Still in Early StagesWallstreetcn·Feb 26 at 05:18 AM000661+1.97%
"Northeast Medicine Mogul" Transforms into Innovative PharmaceuticalsWallstreetcn·Dec 16, 2025 at 09:10 PM000661+1.97%
Zhitong A-share lock-up release overview | November 4Zhitong·Nov 3, 2025 at 07:01 PM600415+6.93%002643+0.31%
CCHT: GenSci134 injection domestic production drug registration clinical trial application approvedZhitong·Nov 3, 2025 at 05:03 AM000661+1.97%
CCHT's subsidiary has received approval for the clinical trial application for the domestic production of the injectable GenSci143 drugZhitong·Oct 31, 2025 at 08:50 AM000661+1.97%
CCHT: Accumulated nearly 400 million yuan to repurchase company shares for incentivesZhitong·Oct 31, 2025 at 02:51 AM000661+1.97%
CCHT released its performance for the first three quarters, with a net profit attributable to the parent company of 1.165 billion yuan, a year-on-year decrease of 58.23%Zhitong·Oct 30, 2025 at 10:47 AM000661+1.97%
CCHT: Clinical trial approval for the domestically produced injectable GenSci139Zhitong·Oct 20, 2025 at 05:54 AM000661+1.97%
CCHT: Clinical trial application for GenSci143 injection has been acceptedZhitong·Oct 17, 2025 at 03:53 AM000661+1.97%
A-share innovative drug concept stocks fluctuated lower, with BETTA PHARMACEUTICALS falling over 10%, Jincheng Pharm, Konruns, Baillie Tianheng, Olymvax Biopharmaceuticals, and CCHT all dropping more than 5%Zhitong·Oct 14, 2025 at 01:11 AM300233+1.99%000661+1.97%
Innovative drug concept experiences a surge, CCHT rises over 8%Zhitong·Oct 9, 2025 at 09:05 PM688331-1.10%09995-2.36%
